ZRC 3308
Alternative Names: ZRC-3308Latest Information Update: 28 Jun 2025
At a glance
- Originator Zydus Cadila
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in India (Parenteral)
- 27 May 2021 Preclinical trials in COVID-2019 infections in India (Parenteral) before May 2021
- 27 May 2021 Zydus Cadila announces intention to submit clinical trial application to Drugs Controller General of India (DCGI) for COVID-2019 infections